Stock AnalizZimmer Biomet (ZBH) earnings for the quarter ended September 2026: EPS beats estimates
Zimmer Biomet reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at $1.90 against the analysts’ average forecast of $1.88, a beat of 1.0%.
Revenue for the quarter was $2.06 billion, up 3.1% from $2.00 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 10.1% on the first trading day after the report.
The last four quarters
Zimmer Biomet has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $1.90 | $1.88 | +1.0% | +3% | +10.1% |
| Jun 2026 | $2.07 | $2.01 | +3.0% | +5% | +1.4% |
| Mar 2026 | $2.09 | $1.86 | +12.2% | +9% | −13.5% |
| Sep 2025 | $1.90 | $1.87 | +1.8% | +10% | −14.2% |
What comes next
Analysts expect EPS of $2.49 for the next quarter on average and $8.55 for the fiscal year ending December 31, 2026.
The average analyst price target is $116.19, 13% above the current price of $103.21.
Valuation and score
Zimmer Biomet scores 2.2 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 26.1, and its intrinsic value under moderate assumptions is about 12% below the current market value. Full Zimmer Biomet analysis with 10 years of financials
Frequently asked questions
What was Zimmer Biomet’s EPS for the quarter ended September 2026?
$1.90 adjusted per share, against an analyst consensus of $1.88.
How much revenue did Zimmer Biomet report?
$2.06 billion, up 3.1% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.